




Barcelona Clinic Liver Cancer (BCLC) guidelines¹



Radioembolization included in BCLC guidelines for Very Early Stage (0) and Early Stage (A) - driven by the LEGACY data^{2,3} - and select Intermediate Stage (B)

Table below shows patient percentage across applicable BCLC stage(s) for each landmark study or trial.

	Very Early Stage (0)	Early Stage (A)	Intermediate Stage (B)	Advanced Stage (C)	End Stage (D)
LEGACY³	60%			40%	
TARGET⁴		13%	32%	55%	
DOSISPHERE-01⁵			9%	91%	
RASER⁶	100%				
PROACTIF⁷		13%	19%	58%	6%

TheraSphere not indicated for patients with macrovascular (e.g. portal) invasion.

THERASPHERE™ Y-90 Glass Microspheres

* Except when tumor burden is within LT criteria.

^ Resection for single peripheral HCC with adequate remnant volume should, when feasible, be performed minimally invasive.

& EBRT or resection may be considered prior to systemic treatment in BCLC A.

**1st Line systemics: Atezolizumab-Bevacizumab/Tremelimumab-Durvalumab/ Camrelizumab-Rivoceranib/ Ipilimumab-Nivolumab If not feasible Sorafenib/Lenvatinib /Durvalumab/Tislelizumab

2nd Line: Post-Sorafenib - Regorafenib (sorafenib-tolerant)

Cabozantinib

Ramucirumab

(AFP \geq 400 ng/mL),

3rd Line: Cabozantinib

Clinical Trials if none of the above feasible

1. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. Published online October 27, 2025. doi:10.1016/j.jhep.2025.10.020
2. Reig M et al., BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update Journal of Hepatology (2021), doi: <https://doi.org/10.1016/j.jhep.2021.11.018>.
3. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
4. Lam, Marnix. A Global Study of Advanced Dosimetry in the Treatment of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres: Analyses from the TARGET Study. Presented at SIR. March 25, 2021.
5. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy inpatients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021; 6: 17-29
6. Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study [published online ahead of print, 2022 May 23]. Lancet Gastroenterol Hepatol. 2022;S2468-1253(22)00091-7. doi:10.1016/S2468-1253(22)00091-7
7. Guiu B, Bailly C, Vibert E et al. Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients. eClinicalMedicine, 2026; 95



TheraSphere™ Y-90 Glass Microspheres Indications, Safety, and Warnings

<https://www.bostonscientific.com/therasphere-indications>

**Boston
Scientific**
Advancing science for life™

Interventional Oncology & Embolization

300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-1394008-AC